These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 35232231)

  • 1. Incidence, predictors and 6-month overall outcome of acute kidney injury in Chinese patients receiving PD-1 inhibitors.
    Qin Z; Liu K; Xu X; Li T; Ge Y; Wu B; Xing C; Mao H
    Future Oncol; 2022 May; 18(16):1951-1962. PubMed ID: 35232231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute kidney injury in advanced lung cancer patients treated with PD-1 inhibitors: a single center observational study.
    Liu K; Qin Z; Ge Y; Bian A; Xu X; Wu B; Xing C; Mao H
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):5061-5070. PubMed ID: 36326913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute kidney injury in patients treated with immune checkpoint inhibitors: a single-center retrospective study.
    Zhou P; Liu B; Shen N; Fan X; Lu S; Kong Z; Gao Y; Lv Z; Wang R
    Ren Fail; 2024 Dec; 46(1):2326186. PubMed ID: 38466161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Liu C; Wei W; Yang L; Li J; Yi C; Pu Y; Yin T; Na F; Zhang L; Fu P; Zhao Y
    Front Immunol; 2023; 14():1173952. PubMed ID: 37313406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence, mortality, and risk factors of acute kidney injury after immune checkpoint inhibitors: Systematic review and meta-analysis of real-world evidence.
    Xie W; Xiao S; Li X; Huang J; Li G; Zhang Z
    Eur J Intern Med; 2023 Sep; 115():88-95. PubMed ID: 37263805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis.
    Abdelrahim M; Mamlouk O; Lin H; Lin J; Page V; Abdel-Wahab N; Swan J; Selamet U; Yee C; Diab A; Suki W; Abudayyeh A
    Oncoimmunology; 2021 May; 10(1):1927313. PubMed ID: 34104543
    [No Abstract]   [Full Text] [Related]  

  • 7. Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition.
    Hakroush S; Kopp SB; Tampe D; Gersmann AK; Korsten P; Zeisberg M; Tampe B
    Front Immunol; 2020; 11():624547. PubMed ID: 33552089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence, risk factors and prognosis of acute kidney injury in patients treated with immune checkpoint inhibitors: a retrospective study.
    Ji MS; Wu R; Feng Z; Wang YD; Wang Y; Zhang L; Sun XF; Chen XM; He KL; Cai GY
    Sci Rep; 2022 Nov; 12(1):18752. PubMed ID: 36335144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
    Franzin R; Netti GS; Spadaccino F; Porta C; Gesualdo L; Stallone G; Castellano G; Ranieri E
    Front Immunol; 2020; 11():574271. PubMed ID: 33162990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Proton Pump Inhibitor Use and Immune Checkpoint Inhibitor-Mediated Acute Kidney Injury: A Meta-Analysis and a Review of Related Outcomes.
    Mohan A; Krisanapan P; Tangpanithandee S; Thongprayoon C; Kanduri SR; Cheungpasitporn W; Herrmann SM
    Am J Nephrol; 2024; 55(4):439-449. PubMed ID: 38471492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute kidney injury associated with anti-PD-1 and anti-PD-L1 drugs: a meta-analysis of randomized clinical trials.
    Lima IG; Silva IBUCD; Pípolo VC; Delfino VDA; Bignardi PR
    Immunopharmacol Immunotoxicol; 2024 Aug; 46(4):470-481. PubMed ID: 38825890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors associated with immune checkpoint inhibitor-induced acute kidney injury compared with other immune-related adverse events: a case-control study.
    Gérard AO; Barbosa S; Parassol N; Andreani M; Merino D; Cremoni M; Laurain A; Pinel S; Bourneau-Martin D; Rocher F; Esnault VLM; Borchiellini D; Sicard A; Drici MD;
    Clin Kidney J; 2022 Oct; 15(10):1881-1887. PubMed ID: 36158153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database.
    Chen P; Zhu J; Xu Y; Huang Q; Su J; Gao Z; Feng M
    BMC Nephrol; 2023 Apr; 24(1):107. PubMed ID: 37087434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review.
    Sise ME; Seethapathy H; Reynolds KL
    Oncologist; 2019 Jun; 24(6):735-742. PubMed ID: 30902916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative risk of acute kidney injury among cancer patients treated with immune checkpoint inhibitors.
    Liu F; Wang Z; Li X; Zhang Z; Yang Y; Chen J; Chen D; Wu L; Liu X; Han S; Wang F; Wahafu W; Gao Y; Ren S; Xing N; Cai G; Chen X
    Cancer Commun (Lond); 2023 Feb; 43(2):214-224. PubMed ID: 36528491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute kidney injury in cancer patients receiving anti-vascular endothelial growth factor monoclonal antibody vs. immune checkpoint inhibitors: a retrospective real-world study.
    Zhu J; Ding X; Zhang J; Chen B; You X; Chen X; Chen T
    BMC Cancer; 2024 Jun; 24(1):756. PubMed ID: 38914959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 Inhibitors.
    Seethapathy H; Zhao S; Strohbehn IA; Lee M; Chute DF; Bates H; Molina GE; Zubiri L; Gupta S; Motwani S; Leaf DE; Sullivan RJ; Rahma O; Blumenthal KG; Villani AC; Reynolds KL; Sise ME
    Kidney Int Rep; 2020 Oct; 5(10):1700-1705. PubMed ID: 33102962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and Prediction of Immune Checkpoint Inhibitor-related Nephrotoxicity.
    Sorah JD; Rose TL; Radhakrishna R; Derebail VK; Milowsky MI
    J Immunother; 2021 Apr; 44(3):127-131. PubMed ID: 32925564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study.
    Espi M; Teuma C; Novel-Catin E; Maillet D; Souquet PJ; Dalle S; Koppe L; Fouque D
    Eur J Cancer; 2021 Apr; 147():29-39. PubMed ID: 33607383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute kidney injury in patients receiving immune checkpoint inhibitors: a retrospective real-world study.
    Lumlertgul N; Vassallo P; Tydeman F; Lewis N; Hobill A; Weerapolchai K; Nordin NZ; Seylanova N; Martin L; Cennamo A; Wang Y; Rigg A; Shaunak N; Ostermann M
    Eur J Cancer; 2023 Sep; 191():112967. PubMed ID: 37499561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.